MSLE
$7.24-0.77 (-9.61%)
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia.
Recent News
Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida Conference
Satellos Bioscience (MSCL.TO, NASDAQ: MSLE) was at last look up near 10% in US premarket trade Tuesd
Satellos price target raised to $40 from $5 at Oppenheimer
Oppenheimer raised the firm’s price target on Satellos (MSLE) to $40 from $5 and keeps an Outperform rating on the shares. The firm is updating its model for U.S. listing, and adjusting for 1:12 reverse split and its increase in Duchenne muscular dystrophy market penetration. Oppenheimer sees Satellos as an arbitrage opportunity in DMD space, wherein SAT-3247 Phase II randomized data could move Satellos up 300%-500%/-90%. President's Day Sale - 70% OffUnlock hedge fund-level data and powerful in
Satellos Closes US$57.2 Million Public Offering in Canada and the United States
Satellos Bioscience (MSCL.TO, MSLE) was last seen down 2% in after-hours Nasdaq trading after the co